Salmon Pharma GmbH - αποτελεσματα

cefuroxim fresenius kabi stungulyfs-/innrennslisstofn, lausn 1500 mg

fresenius kabi ab - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 1500 mg

esomeprazol actavis magasýruþolin tafla 40 mg

actavis group ptc ehf. - esomeprazolum magnesíum - magasýruþolin tafla - 40 mg

lansoprazol krka magasýruþolið hart hylki 30 mg

krka sverige ab - lansoprazolum inn - magasýruþolið hart hylki - 30 mg

bactroban smyrsli 20 mg/g

glaxosmithkline pharma a/s - mupirocinum inn - smyrsli - 20 mg/g

bactroban nasal nefsmyrsli 20 mg/g

glaxosmithkline pharma a/s - mupirocinum kalsíum - nefsmyrsli - 20 mg/g

ceftriaxona normon innrennslisstofn, lausn 2000 mg

laboratorios normon, s.a. - ceftriaxonum dínatríum - innrennslisstofn, lausn - 2000 mg

ceftriaxona normon stungulyfs-/innrennslisstofn og leysir, lausn 1000 mg

laboratorios normon, s.a. - ceftriaxonum dínatríum - stungulyfs-/innrennslisstofn og leysir, lausn - 1000 mg

cefuroxim fresenius kabi stungulyfs-/innrennslisstofn, lausn 750 mg

fresenius kabi ab - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 750 mg

cefuroxim navamedic (cefuroxim villerton) stungulyfsstofn, lausn/dreifa 250 mg

navamedic asa - cefuroximum natríum - stungulyfsstofn, lausn/dreifa - 250 mg

dalacin hart hylki 150 mg

pfizer aps - clindamycinum hýdróklóríð - hart hylki - 150 mg